Neisseria Meningitides Meningitis - Pipeline Insight, 2024

Neisseria Meningitides Meningitis - Pipeline Insight, 2024

DelveInsight’s, Neisseria Meningitides Meningitis - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Neisseria Meningitides Meningitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Neisseria Meningitides Meningitis Understanding

Neisseria Meningitides Meningitis: Overview

Meningococcal disease is caused by bacteria called Neisseria meningitidis. People with meningococcal disease spread the bacteria to others through close personal contact such as living together or kissing. A person with meningococcal disease needs immediate medical attention. It is a human-specific bacterium that causes a multitude of illnesses, collectively termed meningococcal disease. Surprisingly, up to 10% of the general population carries the bacteria in their nose and throat without any adverse effects. Neisseria meningitidis is associated with many infections. However, its association with fulminant meningococcemia and meningococcal meningitis is what has led to its significant impact. More importantly, despite recent vaccine campaigns to help reduce complications of this disease, its effects are still impacting at-risk populations.

The symptoms of meningococcal disease can vary based on the type of illness. Common symptoms of meningococcal meningitis include sudden fever, headache, and stiff neck. Other symptoms may include nausea, vomiting, increased sensitivity to light, and confusion. Children and infants may show different signs and symptoms, such as inactivity, irritability, vomiting, or poor reflexes.

""Neisseria Meningitides Meningitis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neisseria Meningitides Meningitis pipeline landscape is provided which includes the disease overview and Neisseria Meningitides Meningitis treatment guidelines. The assessment part of the report embraces, in depth Neisseria Meningitides Meningitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neisseria Meningitides Meningitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Neisseria Meningitides Meningitis. The therapies under development are focused on novel approaches to treat/improve Neisseria Meningitides Meningitis.

Neisseria Meningitides Meningitis Emerging Drugs

PF 06886992: Pfizer

PF 06886992 is a pentavalent, prophylactic vaccine being developed by Pfizer for the prevention of meningococcal infections, including serogroups A, B, C, meningococcal infection. Pfizer’s pentavalent meningococcal vaccine candidate (PF-06886992) combines its two approved meningococcal vaccines, Nimenrix™ (meningococcal group A, C, W-135, and Y conjugate vaccine) and Trumenba® (meningococcal group B vaccine).

Further product details are provided in the report……..

Neisseria Meningitides Meningitis: Therapeutic Assessment

This segment of the report provides insights about the Neisseria Meningitides Meningitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Neisseria Meningitides Meningitis

There are approx. 15+ key companies which are developing the therapies Neisseria Meningitides Meningitis. The companies which have their Neisseria Meningitides Meningitis drug candidates in the most advanced stage, i.e phase III include Pfizer

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Neisseria Meningitides Meningitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neisseria Meningitides Meningitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neisseria Meningitides Meningitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neisseria Meningitides Meningitis drugs.

Neisseria Meningitides Meningitis Report Insights

• Neisseria Meningitides Meningitis Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Neisseria Meningitides Meningitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Neisseria Meningitides Meningitis drugs?
• How many Neisseria Meningitides Meningitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neisseria Meningitides Meningitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neisseria Meningitides Meningitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neisseria Meningitides Meningitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pfizer
• EuBiologics
• Serum Institute of India
• Hilleman Laboratories
• GlaxoSmithKline
• Beijing Tiantan Biological
• Hilleman Labs
• Sanofi
• Tianjin CanSino Biotechnology
• Inventprise
• AchilleS Vaccines

Key Products

• PF 06886992
• Meningococcus vaccine
• NmCV-5
• GSK 4023393A
• Meningococcal polysaccharide vaccine groups ACYW135
• SP 0230
• CSB 015
• IVTMeningistis 04
• Meningococcal vaccine